Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||71%|
|1 Day Vol Adjusted Return||0.8|
|1 Month Vol Adjusted Return||1.0|
|3 Month Vol Adjusted Return||5.2|
|6 Month Vol Adjusted Return||4.5|
|20 Days SMA Price ZScore||0.2|
|50 Days SMA Price ZScore||0.7|
|12 -26 Days PPO||1.2|
|1 Month Average Short Volume Ratio||29.3|
|1 Day Volume Change ZScore||-1.0|
|1 Month Daily Vol||3.4|
EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company’s Board of Directors has granted fourteen employees nonqualified stock options to purchase an aggregate of 109,000 shares of its common stock with an exercise price of $10.87, which is equal to the closing price of Gritstone’s common stock on November 16, 2
Self-amplifying mRNA (SAM) vaccination protected against SARS-CoV-2 challenge as both a 2-dose regimen and as a single boost following ChAd prime in rhesus macaques Potential for equivalent or more potent immune responses at lower doses with SAM compared to first-generation mRNA vaccines; strong T cell responses observed Initial Phase 1 data from Gritstone-sponsored CORAL study expected early in the first Quarter 2022 EMERYVILLE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nas
Phase 1 data from Gritstone-sponsored CORAL study (SARS-CoV-2 second generation vaccine utilizing self-amplifying mRNA boost) expected in early Q1 2022; CORAL is a multi-trial vaccine program which seeks to drive broad and durable immune responses to SARS-CoV-2 variants Data presented during ESMO 2021 show robust clinical and molecular responses and favorable safety profile across difficult to treat solid tumors with GRANITE (individualized neoantigen program) and SLATE (off-the-shelf shared neo
EMERYVILLE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in five upcoming investor conferences in October, November and December. Conference: B. Riley Fall Best Ideas in Oncology Panel Series – Overcoming Checkpoint Resistance in Solid TumorsDate and Time: Thursday, October 28, 2021 at 1
Every investor in Gritstone bio, Inc. ( NASDAQ:GRTS ) should be aware of the most powerful shareholder groups. Insiders...